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Review Managing hyperemesis gravidarum: a multimodal 
challenge
JK Jueckstock, R Kaestner and I Mylonas*
Abstract
Up to 90% of pregnant women experience nausea and vomiting. When prolonged or severe, this is known as 
hyperemesis gravidarum (HG), which can, in individual cases, be life threatening. In this article the aetiology, diagnosis 
and treatment strategies will be presented based on a selective literature review. Treatment strategies range from 
outpatient dietary advice and antiemetic drugs to hospitalization and intravenous (IV) fluid replacement in persistent 
or severe cases. Alternative methods, such as acupuncture, are not yet evidence based but sometimes have a 
therapeutic effect.
In most cases, the condition is self limiting and subsides by around 20 weeks gestation. More severe forms require 
medical intervention once other organic causes of nausea and vomiting have been excluded. In addition, a 
psychosomatic approach is often helpful.
In view of its potential complexity, general practitioners and obstetricians should be well informed about HG and 
therapy should be multimodal.
Introduction
About 50% - 90% of all pregnancies are accompanied by
nausea and vomiting [1]. According to a study of more
than 360 pregnant women, only 2% experienced only
nausea in the morning whereas, in 80%, complaints per-
sisted throughout the day. The condition is usually self-
limiting and peaks at around 9 weeks gestation. At 20
weeks symptoms typically cease. However, in up to 20%
of cases, nausea and vomiting may continue until delivery
[1].
This condition is known as nausea and vomiting during
pregnancy (NVP) or emesis gravidarum and is of no
pathological significance as long as the affected women
d o  n o t  f e e l  u n w e l l  o r  r e s t r i c t e d  i n  t h e i r  d a i l y  l i f e  [ 2 ] .
There are, however, different grades in the scope of NVP,
which range from occasional morning-sickness to exces-
sive vomiting that persists throughout the day. The most
severe grade of NVP often leads to hyperemesis gravi-
darum (HG; see below), but it can be difficult to differen-
tiate between the two conditions.
A prospective study of more than 9000 pregnant
women showed that NVP occurred significantly more
often in primigravidas and in women who were less edu-
cated, younger, non-smokers and overweight or obese.
The incidence of NVP was also higher in women with a
history of nausea and vomiting in a previous pregnancy
[3].
In order to exclude differential diagnoses the following
crucial parameters should be investigated: Onset of nau-
sea and vomiting (nearly all of the cases begin before 9
weeks of gestation), attendant symptoms, underlying
chronic disorders or, in rare cases, hereditary diseases
(see Figures 1 and 2) [4].
A small percentage of pregnant women experience a
severe form of nausea and vomiting that is termed HG
(synonym: excessive vomiting during pregnancy). This
disorder has an estimated incidence of 0.5% - 2% of all live
births [5]. A standard definition of HG is the occurrence
of more than three episodes of vomiting per day with
ketonuria and more than 3 kg or 5% weight loss. How-
ever, the diagnosis is usually made clinically following the
exclusion of other causes [6,7].
HG can, in individual cases, be life threatening and
treatment must be initiated immediately. Clinical find-
ings include dehydration, acidosis due to inadequate
nutrition, alkalosis due to loss of hydrochloride and
hypokalaemia. There are two degrees of severity: (i) grade
1, nausea and vomiting without metabolic imbalance; and
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Figure 1 Differential diagnosis of nausea and vomiting.
Figure 2 Differential diagnosis of nausea and vomiting in respect to abdominal symptoms.Jueckstock et al. BMC Medicine 2010, 8:46
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(ii) grade 2, pronounced feelings of sickness with meta-
bolic imbalance [2].
In this article the aetiology, diagnosis, clinical presenta-
tion and treatment options will be outlined on the basis
of a selective literature review.
Aetiology
The aetiology of NVP and hyperemesis in pregnancy is
unknown, although some biological, physiological and
psychological as well as sociocultural factors are thought
to be contributory factors [8]. According to another the-
ory, nausea and vomiting during pregnancy might be an
evolutionary adaptation that prevents the intake of
potentially noxious food. Such harmful substances may
b e  p a t h o g e n i c  m i c r o o r g a n i s m s  i n  m e a t  a n d  t o x i n s  i n
strong-tasting vegetables and beverages. Thus, by avoid-
ing the ingestion of those toxic components, it is sup-
posed that the embryo is protected from miscarriage.
Interviews on more than 5400 pregnant women obtained
from 20 studies of gestational aversions, as well as enqui-
ries on more than 6200 pregnant women obtained from
21 studies of gestational cravings, show that most women
during pregnancy prefer food categories that are less
likely to contain toxic substances [9]. However, severe
forms of NVP (such as HG) always require medical inter-
vention.
Risk factors for HG include multiple pregnancy, nulli-
parity, obesity, metabolic disturbances, a history of HG in
a previous pregnancy, trophoblastic disorders, psycho-
logical disorders (for example, eating disorders such as
anorexia nervosa or bulimia) and a history of migration
[10-12].
Human chorionic gonadotrophin (HCG)
HCG is the most likely endocrine factor which accounts
for the development of HG. This conclusion is based on
observed associations between increased production of
HCG (as in molar or in multiple pregnancies) [13-15] and
the fact that the incidence of hyperemesis is highest at the
time when HCG production reaches its peak during preg-
nancy (around 9 weeks gestation) [13]. However, there is
no evidence to support this hypothesis and some preg-
nant women do not experience nausea and vomiting
despite elevated HCG-levels. In addition, patients suffer-
ing from chorionic carcinoma - a disease that is also asso-
ciated with an increase in HCG - do not usually
experience vomiting. These controversial findings may be
caused by the varying biological activity of different iso-
forms of HCG as well as an individual sensitivity for eme-
togenic stimuli. Additionally, hormone-receptor
interactions may modify the effects of HCG leading to
hyperemesis in some cases but having no emetic conse-
quences in others [5].
Helicobacter pylori infection
Chronic infection with helicobacter pylori may also cause
HG [16-22]. The histological examination of the gastric
mucosa in a total of 30 women (20 HG patients and 10
pregnant volunteers) showed that the bacterium was
present in almost 95% of patients with hyperemesis but in
only 50% of controls. The differences between the two
groups were statistically significant (P = 0.009) [16]. In a
metaanalysis of 14 case-control studies, which included a
total of 1732 patients and controls, an association
between the presence of helicobacter pylori and HG was
suggested, although not all of the analysed studies
reached statistical significance [odds ratio from 0.55 to
109.33, confidence interval (CI) 95%] [6]. Nevertheless, in
one study examining both saliva (61.8% detection of heli-
cobacter pylori in patients with HG versus 27.6% in
symptom-free pregnant women) and serum (52.9% ver-
sus 20.7%) for the bacterium results were significant (P <
0.0001, CI 95%) [17], as were cytotoxin-associated gene A
and serum findings in a Chinese study [19]. Two observa-
tional studies of five patients with HG reported no
improvement in symptoms in response to standard drug
treatment. However, a marked response was seen follow-
ing antibiotic treatment (erythromycin) for helicobacter
pylori [18,22]. Therefore, although a helicobacter pylori
infection might not be the only cause of HG, it should be
taken into consideration as a contributing factor in
intractable cases of this condition.
Hormonal factors
Several hormones may cause hyperemesis. These are
oestrogen, progesterone, adrenocorticotropic hormone
(ACTH), cortisol, growth hormone and prolactin. Evi-
dence for the involvement of serotonin in chemotherapy-
induced nausea and vomiting was found some years ago
[23,24] implying that this hormone might also play an
important role in HG but findings have been inconsis-
tent: In a prospective study on a total of 33 women (13
patients suffering from hyperemesis, 10 healthy pregnant
women and 10 nongravid women) serotonin levels were
evaluated. The results showed no differences between the
three groups [25].
Progesterone
Lower [12] and elevated [26] progesterone levels have
been reported in patients with hyperemesis. These altera-
tions are caused by pregnancy-associated changes in the
mother's immune system: In a prospective study on 44
pregnant women (22 patients with hyperemesis and 22
matching healthy pregnant women) a significant increase
in plasma progesterone levels was shown in women with
hyperemesis compared to women without the condition
(P < 0.05). A potentially emetogenic elevation of HCG
due to these modifications is proposed [12]. Lower pro-Jueckstock et al. BMC Medicine 2010, 8:46
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gesterone levels were found in a prospectively controlled
study with 62 NVP subjects versus 40 nonaffected preg-
nant women (P < 0.02) [12]. However, several other stud-
ies found no association between serum progesterone
concentration and hyperemesis [14,27]. Progesterone
may cause reduced gastrointestinal motility during preg-
nancy [28]. Gastric dysrhythmias (tachygastria, brady-
gastria) may also occur [29], thus contributing to
hyperemesis.
Oestrogens
Increased levels of oestrogen and oestradiol are known to
cause nausea and vomiting in pregnancy [30]. Hence, the
presence of a female foetus is associated with severe nau-
sea and vomiting [31,32] usually explained by a raised
concentration of oestrogen in utero [31]. This is consis-
tent with the observation that oestrogen treatment can
cause nausea. It has been suggested that patients with
hyperemesis are probably more sensitive to oestrogen
effects than asymptomatic pregnant women [12]. Ciga-
rette smokers usually show lower levels of both oestro-
gens and HCG. Consistently, HG occurs less often in
women who smoke [33,34]. However, some studies have
reported negative results regarding the association
between elevated oestrogen levels and the development
of hyperemesis [35].
Hyperthyroidism
Thyroid function is physiologically altered during preg-
nancy, including stimulation by HCG [36]. Hyperthyroid-
ism with normal fT3 and fT4 levels, but decreased levels
of thyroid stimulating hormone (TSH), may also be impli-
cated in HG [37,38]. A self-limiting, transient hyperthy-
roidism of hyperemesis gravidarum (THHG) has been
proposed according to the findings of a screening series
in 1900 pregnant women who showed markedly
increased HCG and fT4 levels [36]. THHG may persist
until 18 weeks gestation and does not require treatment.
This condition may be partly caused by the high levels of
HCG that are often seen in patients with HG since HCG
and TSH have a very similar protein structure, thus
enabling HCG to act like TRH and hyper-stimulate the
thyroid, which recently has been shown conclusively
[39,40].
Assignment of a diagnosis of THHG requires the fol-
lowing [2]:
• pathological serology results during hyperemesis
• a negative history of hyperthyroidism before the preg-
nancy
• the absence of thyroid antibodies
Psychosomatic approach
Several years ago the theory of underlying psychological
alterations as main causative factor for HG was proposed
[41]. This was partly thought to be due to a lack of evi-
dence of any straight biological pathophysiological path-
way [42], partly due to the finding that many patients
seem to need psychological help to cope with the condi-
tion.
Not only is their physical identity profoundly changed
by the pregnancy but also their daily social life. One for-
mer commonly used explication for development of HG
was a psychiatric explanation of vomiting as a subcon-
scious wish for an abortion or - in a different approach - a
conversion disorder underlying the condition [43].
Although this might be the cause in individual cases,
nowadays the generally accepted opinion is that severe
psychological afflictions are a consequence of constant
vomiting rather than the source of it [8,13]. Such a psy-
chiatric sequel may continue even postpartum [10]. Per-
haps as a reaction to the psychological strain of the
patients, during the last years psychological treatment
approaches seem to increase to a varying extent in differ-
ent countries [44].
Davis et al. found no differences in the incidence of HG
in association with marital status, whether or not the
pregnancy was desired, or the patient's attitude towards
the pregnancy [45]. The most frequently cited study used
the psychological Cornell Medical Index to assess 44
pregnant women with, and 49 pregnant women without,
HG [35]. A further study used the MMPI to assess
patients with HG [46]. Both studies showed that women
with hyperemesis had an excessive emotional bond to
their mothers and that the main types of personality were
hysterical and infantile. Additionally, a systematic ques-
tionnaire based on interviews with 23 hospitalized
women with HG showed suppressed ambivalent feelings
of the expectant mothers towards their pregnancies that
were expressed in severe vomiting [47], but this associa-
tion has not been proven to a sufficient extent [42]. Based
on a case control study in more than 11,000 pregnant
women an association between pre-pregnancy diagnosed
psychiatric conditions (for example, depression, anxiety
or drug abuse) and HG was seen (P < 0.001) [48]. How-
ever, these studies have to be evaluated critically because
of a potential methodological weakness [42].
More recent approaches assume that neither a merely
physical pathway nor a completely psychological path-
omechanism can cause such a complex disease but on the
contrary HG is a multifactorial condition. Focusing
entirely on psychogenic factors raises the risk that
patients are not taken seriously in their suffering and
probably not all existing therapeutic options are used.
However, neglecting the psychosomatic aspects in the
d e v e l o p m e n t  a n d  c o u r s e  o f  H G  i n  s o m e  p a t i e n t s  h a r -
bours the risk of treating only the symptoms of the condi-
tion without eliminating the cause.Jueckstock et al. BMC Medicine 2010, 8:46
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Medical history and clinical presentation
Clinical symptoms are usually non-specific and it is
important to exclude the more unusual causes of nausea
and vomiting. These include peptic ulceration, hepatitis,
pancreatitis, thyroid disease, gastrointestinal obstruction
and adrenocortical insufficiency (see Table 1) [13]. An
onset of symptoms after 10 weeks gestation is atypical for
NVP and systematic exclusion of the diseases mentioned
above is particularly important in such cases.
NVP usually has very few attendant symptoms other
than fatigue, exhaustion and indisposition. Pyrexia, gas-
tric pain, headache or neurologic signs point to other
causes, although the latter finding may, in rare cases,
result from severe and prolonged NVP (for example,
Wernicke's encephalopathy or central pontine myelinoly-
sis). In the case of elevated thyroid hormones, it is impor-
tant to distinguish between THHG and primary thyroid
disease. Furthermore, chronic underlying conditions that
m a y ha ve  bee n e xa c er ba t ed o r un mas k ed by  t he  pr eg-
nancy should be excluded [5].
Metabolic ketoacidosis and ketonaemia (acetone-like
breath) may also occur with occasional pyrexia and
hepatic symptoms (for example, jaundice). In some cases,
drowsiness and intellectual slowness are present and this
may lead to delirium. Laboratory investigations should
include haematocrit, electrolytes, transaminases, biliru-
bin and thyroid function tests as well as urinary status
(presence or absence of ketone bodies, specific weight,
pH). In addition, ultrasonography should be performed in
order to exclude multiple pregnancy, trophoblastic disor-
ders and neoplasias. If a psychic component of the disor-
der is suspected, ultrasound scans should not be repeated
too often as this may aggravate psychosomatic symptoms
[49].
In order to diagnose underlying psychological factors, a
psychosomatic dialogue aiming at the formation of a
working alliance between patient and physician is essen-
tial [50]. This often reveals a stressful and intolerable situ-
ation in the patient's social environment that she is
unable to escape from or avoid. This psychosocial distress
is then converted into a somatic symptom [51]. In the
case of persistent vomiting or conspicuous symptoms the
psychological differential diagnosis should include deep
and defended psychic conflicts [2].
Treatment strategies
Treatment strategies for HG should be based on the
severity of symptoms and multimodal in nature (advice,
hydration, medication, hospitalization and psychoso-
matic counselling when necessary; see Figure 3). The
severity of the condition can be assessed by numerous
questionnaires. Two of the most widely used question-
naires are the Pregnancy-Unique Quantification of Eme-
Table 1: Diseases associated with nausea and vomiting 
during pregnancy (alphabetical order), adapted from 
reference .
Causes Differential diagnosis
Gastrointestinal causes Appendicitis
Diaphragmatic hernia
Gastroenteritis
Hepatic or cholecystic disorders
Hepatitis
Ileus and subileus
Pancreatitis
Stomach cancer
Stomach ulcer or duodenal ulcer
Metabolic causes Addison's disease
Diabetic ketoacidosis
Hyperthyroidism
Porphyria
Thyrotoxicosis
Neurological causes Korsakoff's psychosis
Migraine
Vestibular disorders
Wernicke's encephalopathy
Pregnancy associated Acute fatty liver
Emesis gravidarum (<5 ×/day)
Hyperemesis gravidarum (>5 ×/day)
Multiple pregancyJueckstock et al. BMC Medicine 2010, 8:46
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sis and Nausea (PUQE) scoring index, which assesses
nausea and vomiting over 12 h, and the PUQE-24, an
extension of the original PUQE, which assesses symp-
toms over 24 h [52,53]. Another recently developed score
is the Hyperemesis Impact of Symptoms Questionnaire
(HIS) that brings into focus not only physical but also
psychosocial factors in order to assess the impact of HG
holistically [54].
Initial management
For initial management, dietary and lifestyle advice is
often sufficient to ameliorate symptoms and improve
quality of life. Mild forms of nausea and vomiting can
usually be managed by following general nutritional
advice such as the intake of small amounts of fluids and
food throughout the day rather than eating fewer but
larger meals. Foods should be rich on carbohydrates and
low in fat and acid [2]. Light snacks, nuts, dairy products,
beans and dry and salty biscuits are also frequently rec-
ommended. Additionally, electrolyte-replacement drinks
and oral nutritional supplements are advisable for ensur-
ing maintenance of electrolyte balance and an adequate
intake of calories. Protein-predominant meals have a pos-
itive effect because they are eupeptic and are able to
reduce nausea more effectively than equicaloric carbohy-
drate and fat meals or noncaloric meals [55]. If the smell
of hot food triggers nausea, cold food should be prepared
instead. Lifestyle advice may include avoiding stress and
resting in the event of incipient nausea.
Emotional support and, if needed, psychosomatic care
administered by a psychologist or a medical doctor with
training in psychosomatics can be helpful. Depending on
the severity of the symptoms, supportive counselling or
crisis intervention might be required [2].
Medication
If symptoms cannot be managed by dietary and lifestyle
changes alone, low dose antiemetics may be adminis-
tered. All pharmacologic interventions should be based
upon known safety, proven efficacy and cost effectiveness
[56].
In a metaanalysis of 28 randomized trials of medica-
tions for the treatment of HG, antiemetics diminished
nausea in early pregnancy and were superior to placebo
[2]. Ondansetron is one of the more commonly used and
effective drugs and has relatively few side effects
[13,57,58].
Other recommended options are the use of metoclopr-
amide to improve gastrointestinal motility and adminis-
tration of pyridoxine (vitamin B6) [59]. Pyridoxine is
given three times daily at a dose of 10 - 25 mg starting
with a low dose that may reduce symptoms and has been
proven to be more effective than placebo [13,60]. The
daily dose can be increased up to 200 mg without side
effects [61,62]. However, a more recent placebo-con-
trolled trial demonstrated that a combination of oral pyr-
idoxine and metoclopramide did not improve the
vomiting frequency or the nausea score [63].
Antihistamines and anticholinergics such as meclizine,
dimenhydrinate and diphenhydramine have also been
shown to be superior to placebo and can be used safely
for the treatment of nausea and vomiting in pregnancy
(see Table 2) [64].
However, the side effect profiles vary between the dif-
ferent medications: While nearly all of the above men-
tioned medicaments may cause dizziness, drowsiness,
constipation or dry mouth, more severe adverse effects
comprise convulsions, decreased alertness, heartbeat
alterations and hallucinations (doxylamine, metoclopr-
amide, diphenhydramine, dimenhydrinate, promethaz-
ine). Headache, muscle pain or tremor and fever
(prednisolone, procholrperazine, promethazine, dimen-
hydrinate, doxylamine, metoclopramide) may also occur.
Interestingly, diazepam also has positive effects on HG,
probably due to its sedative properties [65]. A prospective
r a n d o m i z e d  c l i n i c a l  t r i a l  i n  7 4  p a t i e n t s  s h o w e d  t h a t  a
combination of antiemetic therapy and diazepam
reduced the need for hospitalization and improved
patient satisfaction [56]. Frequent use of diazepam, how-
ever, might lead to dependency. Another risk factor that
must be taken into consideration is the possibility of fetal
side effects [2,66]. Antidepressants such as mirtazapine
have also been used with some success in ameliorating
the symptoms of HG [67].
Pre-eclampsia
Premature contractions
Urogenital causes Degenerative uterine fibroids
Nephrolithiasis
Pyelonephritis
Uremia
Other causes Drug poisoning
Food poisoning
Iron medication
Table 1: Diseases associated with nausea and vomiting 
during pregnancy (alphabetical order), adapted from 
reference . (Continued)Jueckstock et al. BMC Medicine 2010, 8:46
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Non-pharmacological interventions
Alternative treatments include acupressure, especially on
the P6 point (Neiguan) on the inside of the wrist [68,69].
However, despite several trials, there is still minimal
experimental evidence that acupuncture is effective in
relieving the symptoms of HG., A supplement that may
be helpful is ginger. In a trial of 66 women ginger (1 g/
day) compared to placebo was shown to be of benefit for
those suffering from both nausea and vomiting [70].
Another prospective study of 187 pregnant women with
symptoms of NVP showed that ginger had a mild effect in
ameliorating nausea and vomiting without negative
effects on the fetus [71]. Available data show that ginger
has no apparent teratogenic potential and can be used
safely up to a daily dose of 1 gram [5,62,72-75].
Hospitalization
In patients with more severe dehydration or ketonuria,
inpatient admission is required (see Figure 3). Sometimes
hospitalization alone is sufficient to improve symptoms
('holding function') because it may provide psychological
relief. However, the treatment of dehydration is consid-
ered to be of paramount importance [13].
The primary therapeutic step is total food withdrawal.
Maintaining hydration or, in the case of severe dehydra-
tion achieving quick and sufficient rehydration, is the
most important intervention. Volume and electrolyte
replacement (at least 3 L/day), correction of potential
electrolyte imbalance, administration of vitamins and
parenteral administration of carbohydrate and amino
acid solutions (about 8400 to 10,500 kJ/d) are recom-
mended (see Table 3). Rehydration is most easily and
quickly accomplished intravenously and this reduces
adverse symptoms very effectively.
Although peripheral catheters are considered to be
advantageous, a study of 94 patients with HG reported
the occurrence of a substantial number of complications
in association with peripherally inserted central catheters
(PICC lines) compared to treatment with medication
only. This suggests that invasive treatment options should
be thoroughly investigated before being introduced [76].
Major complications associated with PICC lines are
Figure 3 Multimodal character of treatment strategies in hyperemesis gravidarum, adapted from reference [2].Jueckstock et al. BMC Medicine 2010, 8:46
http://www.biomedcentral.com/1741-7015/8/46
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infections and thrombosis or endocarditis. In a retro-
spective study of 85 pregnant women with central cathe-
ters, 25% developed serious complications including
infections (12%) [77]. To date, no fetal or maternal medi-
cal benefit has been found for PICC lines in comparison
to serial peripheral catheters and the use of central cathe-
ters is only recommended in exceptional cases [78].
An alternative to parenteral nutrition may be nasogas-
tric feeding tubes because, in cases of intractable nausea
and vomiting, they seem to relieve symptoms and provide
adequate nutritional support [79]. Another advantage of
enteral feeding via nasogastric tubes in comparison to
parenteral nutrition is that enteral feeding is more cost
effective [80]. In order to determine whether an underly-
ing helicobacter pylori infection is (partially) causative,
helicobacter pylori testing may be performed. In the
event of a positive result, H2 blockers (for example, cime-
tidine) or proton pump inhibitors (for example, omepra-
zol) can be added to infusions [20,81-83].
If hyperemesis is refractory to treatment, corticoids (for
example, hydrocortisone) may also be used [84]. Corti-
costeroids are considered to be safe and have no known
adverse effects for the fetus. IV administration may be
preferable to oral administration, particularly in refrac-
tory cases, as the effect is greater and more rapid [84].
Total parenteral nutrition (TPN) may be useful in
highly refractory cases in order to ensure a sufficient cal-
orie intake [85]. However, there is no evidence to support
the use of TPN and it should only be used as a last resort
when all other treatments have failed, as it can be associ-
ated with severe complications such as thrombosis, meta-
bolic disturbances and infection [86].
In patients with persistent symptoms, other disorders
should be excluded (see Figures 1 and 2). Treatment
should be continued until vomiting ceases or occurs less
than three times a day. Subsequent food reintroduction
should be carried out gradually [2].
Psychosomatic therapeutic options
Psychosomatic therapies involve dialogues between the
physician and the pregnant woman to evaluate the psy-
chosocial situation in her marital relationship, activate
Table 2: Antiemetic agents and supposed dosage in hyperemesis gravidarum, adapted from references 
Food and Drug 
Admnistration category
Medication Administration Suggested dosage
A Pyridoxine (vitamin B6) Oral 20 mg 3 × per day (max. dose: 200 mg per day)
Doxylamine Oral 25 mg at night and 12.5 mg in the morning 
accompanied by 10 mg of pyridoxine (maximum 
dose: 80 mg per day)
B Ondansetron Oral/intravenously (IV) 4-8 mg 2-3× per day/2-4 mg every 6-8 h or 8 mg every 
12 h IV
Metoclopramide Oral 5-10 mg 3-4 × per day
Meclizine Oral/rectal 25-100 mg 2-4 × per day/1 × per day
Diphenhydramine Oral/IV 25-50 mg every 6-8 h
Dimenhydrinate Oral/IV/rectal 50 mg 3-4× per day/62 mg 2× per day/1-3× per day
C Promethazine Oral/IV 12.5-25 mg up to 6 × per day
Prochlorperazine Rectal 25 mg per day or 2× per day
Prednisolone Oral 40-60 mg per day reducing by half every 3 days
- Ginger Oral (biscuits, confectionary, 
crystals, powder, tablets, 
capsules, fresh ginger)
Up to 1 g per day in divided dosesJueckstock et al. BMC Medicine 2010, 8:46
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individual resources and provide support regarding
acceptance of the pregnancy. On the basis of anamnestic
data, other proper therapeutic options such as hypno-
therapy, psychotherapy or behavioural therapy may be
considered. In approximately 90% of all women hospital-
ized for HG, symptoms ameliorate without any further
therapeutic intervention. This may be due to inpatient
nursing support and relief from overstraining, as well as
to being removed from the conflict-causing environment.
Nevertheless, consideration of psychosocial factors while
making the diagnosis may improve long-term treatment
outcome [87].
Pregnancy outcome and prognosis
In most cases, nausea and vomiting during pregnancy is
self limiting and is usually resolved by around 20 weeks
gestation [13]. Interestingly, it is consistently associated
with lower rates of miscarriage, retarded intrauterine
growth and preterm delivery and fetal outcomes are, in
most cases, excellent [11,88-90].
Other causes of severe distress in these patients include
loss of time from work and a reduced quality of life [1].
An investigation of 147 patients evaluated the impact of
NVP on family, social and occupational functioning as
well as quality of life. It found that 82.8% of patients were
limited in their usual daily activities, not only by the pres-
ence of constant nausea and frequent vomiting, but also
by the psychological burden of not feeling well for several
weeks or months [91]. Another stressful aspect of the dis-
order is the change of the patient's role within her social
or occupational environment: Many women feel helpless
and incapable and misunderstood by their relatives. Fam-
ily problems range from neglect of the household to neg-
ative alterations in the relationship between the pregnant
woman and her spouse. Social functioning is often
affected, with a reduction in social commitments, partly
due to feelings of embarrassment. Most patients with
severe NVP or HG miss at least a few weeks of their paid
employment and report that they are less attentive to
their work [91].
NVP and HG may cause considerable direct (for exam-
ple, medication) and indirect (for example, loss of pro-
ductivity) costs, which can amount to hundreds of
dollars. These costs apply not only to the patients, but
also to society and the health care system [92]. More seri-
ous medical complications include the Mallory-Weiss
syndrome (acute increase in oesophageal pressure due to
vomiting) and oesophageal rupture (due to severe vomit-
ing), pneumothorax, peripheral neuropathy, coagulopa-
thy, Wernicke's encephalopathy (due to lack of thiamine),
pre-eclampsia and fetal growth retardation [11,13,93-95].
The psychosomatic aspects of hyperemesis should also
be considered. Interestingly, psychosocial morbidity for
the mother often presents in the form of secondary
depression, which affects up to 7% of patients with HG
[10,96]. Therefore, adequate assessment, observation,
and treatment of a possible psychosomatic disorder
should also be considered.
Conclusions
Since the causal factors of HG are multifarious, treatment
of this condition should be multimodal, ranging from
dietary and lifestyle advice to psychosomatic counselling
or psychoanalytic therapy. Administration of antiemetic
drugs may be necessary, as well as IV fluid replacement,
food administration via nasogastric or parenteral routes
Table 3: Recommended procedure for substitution of vitamins during total parenteral nutrition (personal communication 
Ramsauer and Vetter, Berlin, Germany).
Parenteral nutrition via peripheral venous access
Main infusion Adjuvants (daily dose) Speed of operation
500 mL glucose-infusion 5% • 200 mg vitamin B1 (thiaminchloride),
• 200 mg vitamin B6 (pyridoxine),
• 200 μg vitamin B12 (cyanocobalamine),
• 2000 mg vitamin C (ascorbic acid)
50 mL/h
Parenteral nutrition via central venous access
Main infusion Adjuvants (daily dose) Speed of operation
500 mL glucose-infusion 40% • 200 mg vitamin B1(thiaminchloride),
• 200 mg vitamin B6 (pyridoxine),
• 200 μg vitamin B12 (cyanocobalamine),
• 2000 mg vitamin C (ascorbic acid)
50 mL/hJueckstock et al. BMC Medicine 2010, 8:46
http://www.biomedcentral.com/1741-7015/8/46
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in severe cases. Since this condition is accompanied by a
significant reduction in quality of life for the patient and
high costs to the healthcare system, general practitioners
and obstetricians should ensure that they are well
informed about this condition [97] so that they are able to
provide advice, counselling and effective medication to
pregnant women and thus prevent the exacerbation of
symptoms.
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